News coverage about TESARO (NASDAQ:TSRO) has been trending somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. TESARO earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 44.8180497409008 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the media headlines that may have effected Accern Sentiment’s rankings:

A number of equities research analysts have commented on TSRO shares. Credit Suisse Group set a $198.00 price target on TESARO and gave the company a “buy” rating in a report on Monday, June 5th. Cann reissued a “buy” rating and set a $199.00 price target on shares of TESARO in a report on Monday, June 5th. Oppenheimer Holdings, Inc. set a $199.00 price target on TESARO and gave the company a “buy” rating in a report on Sunday, June 4th. Bank of America Corporation reissued a “buy” rating and set a $154.00 price target on shares of TESARO in a report on Tuesday, June 20th. Finally, Gabelli started coverage on TESARO in a report on Friday, July 7th. They set a “buy” rating and a $175.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. TESARO presently has a consensus rating of “Buy” and an average price target of $171.42.

TESARO (TSRO) opened at 118.74 on Wednesday. The stock’s market cap is $6.43 billion. The company has a 50-day moving average price of $121.03 and a 200 day moving average price of $138.94. TESARO has a 52-week low of $96.52 and a 52-week high of $192.94.

TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the consensus estimate of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The company had revenue of $29.50 million for the quarter, compared to analyst estimates of $18.61 million. During the same quarter last year, the company earned ($1.28) EPS. The firm’s revenue for the quarter was down 17.6% on a year-over-year basis. On average, analysts expect that TESARO will post ($8.67) earnings per share for the current year.

In related news, VP Edward C. English sold 10,862 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the completion of the sale, the vice president now owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Grant C. Bogle sold 14,167 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 25,100 shares of company stock valued at $3,387,465. 34.60% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “TESARO (TSRO) Getting Somewhat Positive Press Coverage, Analysis Shows” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/tesaro-tsro-getting-somewhat-positive-press-coverage-analysis-shows/1574344.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.